XVIVO Perfusion AB
23.9.2021 09:31:49 CEST | ACCESS Newswire | Press release
GOTHENBURG, SE / ACCESSWIRE / September 23, 2021 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)
At the XVIVO Capital Markets Day in Gothenburg, Sweden today, CEO Dag Andersson and other senior executives will focus on the company's strategy to become the world leader in the transplant industry.
XVIVO will present five strategic focus areas for the period 2022 - 2026; Global leader Abdominal (with initial focus on the US); Market leading heart preservation system; Increase penetration of machine perfusion; Secure all-inclusive reimbursement in key geographic areas; and China to become the company's second largest market.
"Strategy is about making choices and about deliberately choosing to be different, and always for us considering our overall vision that nobody should die waiting for a new organ. With our five strategic focus areas we have defined our way forward and the keys to our future success " says Dag Andersson, CEO.
During the Capital Markets Day, financial targets and the actions to reach these targets will be presented. XVIVOs ambition is to reach an EBIT-margin of 20 % and an EBITDA-margin of 30 % during the strategy period. In 2026, Abdominal revenue is expected to be of equal size as Thoracic revenue.
XVIVO will continue to build on its world leading position in lung transplantation and develop the offering to cover all four major organs: lung, heart, kidney and liver.
The Capital Markets Day will be broadcasted live online today, on 23 September 2021, at 13:00 CEST via this link: https://xvivo.creo.se/210923 . A recording of the Capital Markets Day will be available on-demand shortly after the event via the same link.
For further information, please contact:
Kristoffer Nordström, CFO and IR, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
Anne Lycke, Executive Assistant, +46 735 192 146, e-mail: anne.lycke@xvivogroup.com
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-09-23 09:13 CEST.
Attachments
Language correction: XVIVO Capital Markets Day presents strategic focus areas for 2022-2026
SOURCE: XVIVO Perfusion AB
View source version on accesswire.com:
https://www.accesswire.com/665272/XVIVO-Capital-Markets-Day-Presents-Strategic-Focus-Areas-for-2022-2026
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI Mojave First UAS To Complete Battlefield Short Field Ops16.9.2026 19:30:00 CEST | Press release
Short Takeoff and Landing Aircraft Validates Austere Field Capabilities SAN DIEGO, CA / ACCESS Newswire / September 16, 2026 / General Atomics Aeronautical Systems (GA-ASI) and Hanwha Aerospace have completed the first-ever flight operations from a simulated battlefield by a medium altitude, long endurance uncrewed aircraft. The partners proved that the Mojave Short Takeoff and Landing aircraft, or Mojave STOL, could land at a tank and artillery live-fire range during simulated combat conditions and then take off again to continue the mission. "This demonstration showcased Mojave's ability to perform tactical missions that are representative of real battlefield requirements and challenges," said GA-ASI CEO Linden Blue. "Whether the user needs contested and austere battlefield operations, ISR, weapons delivery, Air-Launched Effects deployment, troop resupply, counter-UAS, or missions requiring short and unimproved roads for takeoff, our aircraft answer the bell." "This demonstration mar
Freedom Holding Corp. Named General Partner of the Salesforce FIDE World Championship Match 202616.9.2026 16:13:00 CEST | Press release
Partnership builds on Freedom's long-term support for international chess as Geneva prepares to host the historic Gukesh - Sindarov title match NEW YORK CITY, NY / ACCESS Newswire / September 16, 2026 / Freedom Holding Corp. (NASDAQ:FRHC) will serve as General Partner of the Salesforce FIDE World Championship Match 2026, continuing a long-standing partnership with the International Chess Federation (FIDE) spanning elite competition, education and chess development. Freedom's involvement in the 2026 World Championship follows several years of cooperation with FIDE. The company was General Partner of the 2023 World Championship Match in Astana and title sponsor of the 2024 FIDE World Rapid & Blitz Championships in New York, one of FIDE's flagship global events. It has also supported international competitions and initiatives focused on expanding access to chess, developing young talent and strengthening the wider chess ecosystem. Earlier this year, Freedom and FIDE further expanded their
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics16.9.2026 13:00:00 CEST | Press release
Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care, autoimmune disease, transplantation and oncology Union of two companies brings together Santersus' NucleoCapture® technology, designed to physically remove NETs from circulation, with Xenetic's DNase technology, designed to enzymatically degrade NETs in tissue Joint pipeline includes four first-in-class programs, including pivotal-stage programs in sepsis and systemic lupus erythematosus (SLE), both of which have received FDA Breakthrough Device Designation Companies to host Business Update Conference Call and Webcast Today, Wednesday, September 16th at 8:30 AM ET FRAMINGHAM, MA / ACCESS Newswire / September 16, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company advancing its Deoxyribonuclease ("DNase") technology, and Santersus AG ("Santersus"), a privately held
DataTracks Completes First Live GloBE Filing Cycle, Delivering Close to 500 Pillar Two Filings Across 10+ Jurisdictions16.9.2026 11:15:00 CEST | Press release
HMRC-authorised provider completes close to 500 Pillar Two filings, including more than 150 GIRs, for 160+ clients across 10+ jurisdictions WEYBRIDGE, GB / ACCESS Newswire / September 16, 2026 / DataTracks, recognised by HMRC as an authorised software provider supporting UK Pillar Two submissions, has completed its first live BEPS Pillar Two filing cycle, delivering close to 500 filings, including more than 150 GIRs, across 10+ jurisdictions for more than 160 clients. The milestone caps two decades of work in regulatory reporting. The cycle spanned GloBE Information Returns (GIR), domestic top-up tax returns under local QDMTT (Qualified Domestic Minimum Top-up Tax) regimes, UK Overseas Return Notifications (ORNs), and other jurisdiction-specific returns and notifications. Several jurisdictions in this cycle, including the Netherlands and Luxembourg, require similar notifications confirming where the GIR was filed centrally, under their own local terms. DataTracks filed each return dire
Hydrosat Unveils Osiris Constellation, The Future of Thermal Intelligence16.9.2026 08:00:00 CEST | Press release
Next-generation satellite constellation will combine high-resolution thermal imaging with broad-area coverage and daily revisit to support governments, businesses, and researchers worldwide. PARIS, FR / ACCESS Newswire / September 16, 2026 / Hydrosat, the leading provider of thermal infrared satellite data and AI-powered analytics, today announced Osiris, its next-generation Earth observation constellation designed to deliver wide-area, high resolution intelligence for water and food security, critical infrastructure, and national security missions. At the core of each Osiris satellite is Hydrosat's next-generation thermal infrared payload, developed to collect high-resolution thermal data across exceptionally wide areas. Operating across three longwave infrared bands, the payload will capture imagery at 25-meter native resolution over 160-kilometer to 340-kilometer swath widths, addressing one of Earth observation's biggest challenges between spatial detail and collection scale. This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom